Targeting Lung Cancer Cough
When the cancer is treated but the cough remains, Biovara is tackling what others overlook
Millions suffer in silence, Biovara targets the overlooked burden of Lung Cancer Cough (LCC)
Biovara is addressing a critical, unmet need in oncology care:
the debilitating cough associated with advanced lung cancer.
While the condition affects up to 80% of patients in late-stage disease, no approved treatment currently exists. Backed by peer-reviewed clinical data and a team with proven pharmaceutical and scientific credentials, Biovara is advancing a novel, orally administered therapy that crosses the blood-brain barrier and targets the root cause of lung cancer cough. The root cause of LCC isn’t just in the brain – it is twofold, in the brain and in the lung (caused by the tumour itself).
Biovara is developing a first-in-class solution with clear clinical rationale, substantial patient impact, and significant market potential.
Proven effectiveness to alleviate lung cancer cough conditions
The unmet medical need for a debilitating condition
Innovation delivered by an experienced team
2.5 million people are diagnosed with lung cancer each year
A new, innovative and comprehensive approach to treating Lung Cancer Cough
